Ultrasonographic Follow-up of the Multistep Protocol for Prostate Cancer Induction in Wistar Rats

Overview

Journal In Vivo

Specialty Oncology

Date 2020 Jul 2

PMID 32606149

Citations 1

Authors

Ana I Faustino-Rocha

Fernanda Seixas

Rita Ferreira

Jessica Silva

Maria J Pires

Margarida Fardilha

Mario Ginja

Paula A Oliveira

Affiliations

Soon will be listed here.

Abstract

Aim: This work intended to improve the knowledge of the rat model of prostate cancer (PCa) by ultrasonographic monitoring.

Materials And Methods: Male Wistar rats were divided into control (n=8) and PCa (n=14) groups. PCa development was induced in the PCa group through the sequential administration of the anti-androgenic drug flutamide, testosterone propionate and the carcinogenic N-methyl-N-nitrosourea. The prostate was evaluated by ultrasonography at five timepoints along 49 weeks of the experimental protocol. Ventral prostate lobes were observed in all ultrasonographic examinations.

Results: The ventral prostate area of the control group increased gradually between the first and the last ultrasonographic examination. The ventral prostate area of PCa groups decreased due to flutamide administration and increased after androgen and carcinogen administration. The area of the dorsal prostate lobe increased between the fourth and the fifth ultrasonographic examination. In the last ultrasonographic examination, hypoechoic and anechoic lesions were observed in the PCa group.

Conclusion: To our knowledge, this is the first study presenting a follow-up of rat prostatic dimensions by ultrasonography. Ultrasonography is a feasible approach for prostate cancer monitoring in experimental models.

Citing Articles

Successful hormonal and chemical induction of prostate cancer in a rat model: practical guidelines.

Nascimento-Goncalves E, L Faustino-Rocha A, Seixas F, Colaco B, Ferreira R, Oliveira P Vet Res Forum. 2024; 15(9):445-453.

PMID: 39564469 PMC: 11571041. DOI: 10.30466/vrf.2023.1999343.3838.

References

Di Pietro G, Chornokur G, Kumar N, Davis C, Park J . Racial Differences in the Diagnosis and Treatment of Prostate Cancer. Int Neurourol J. 2016; 20(Suppl 2):S112-119. PMC: 5169094. DOI: 10.5213/inj.1632722.361. View

Shirai T . Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention. Pathol Int. 2007; 58(1):1-16. DOI: 10.1111/j.1440-1827.2007.02182.x. View

Custodio A, Santos F, Campos S, Vilamaior P, Goes R, Taboga S . Aging effects on the mongolian gerbil female prostate (Skene's paraurethral glands): structural, ultrastructural, quantitative, and hormonal evaluations. Anat Rec (Hoboken). 2008; 291(4):463-74. DOI: 10.1002/ar.20637. View

Bosland M . Animal models for the study of prostate carcinogenesis. J Cell Biochem Suppl. 1992; 16H:89-98. DOI: 10.1002/jcb.240501221. View

Kelleher S, Howe C, Conway A, Handelsman D . Testosterone release rate and duration of action of testosterone pellet implants. Clin Endocrinol (Oxf). 2004; 60(4):420-8. DOI: 10.1111/j.1365-2265.2004.01994.x. View

Shirai T, Takahashi S, Cui L, Futakuchi M, Kato K, Tamano S . Experimental prostate carcinogenesis - rodent models. Mutat Res. 2000; 462(2-3):219-26. DOI: 10.1016/s1383-5742(00)00039-9. View

Limonta P, Dondi D, Marelli M, Moretti R, Negri-Cesi P, Motta M . Growth of the androgen-dependent tumor of the prostate: role of androgens and of locally expressed growth modulatory factors. J Steroid Biochem Mol Biol. 1995; 53(1-6):401-5. DOI: 10.1016/0960-0760(95)00086-f. View

Strasser F, Bruera E . Update on anorexia and cachexia. Hematol Oncol Clin North Am. 2002; 16(3):589-617. DOI: 10.1016/s0889-8588(02)00011-4. View

Lee C, Akin-Olugbade O, Kirschenbaum A . Overview of prostate anatomy, histology, and pathology. Endocrinol Metab Clin North Am. 2011; 40(3):565-75, viii-ix. DOI: 10.1016/j.ecl.2011.05.012. View

10.

Kelloff G, Choyke P, Coffey D . Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol. 2009; 192(6):1455-70. PMC: 2893141. DOI: 10.2214/AJR.09.2579. View

11.

Discacciati A, Wolk A . Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014; 202:27-37. DOI: 10.1007/978-3-642-45195-9_3. View

12.

Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vees H, Khan H . (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2006; 34(2):185-96. DOI: 10.1007/s00259-006-0163-x. View

13.

Lau K, Tam N, Thompson C, Cheng R, Leung Y, Ho S . Age-associated changes in histology and gene-expression profile in the rat ventral prostate. Lab Invest. 2003; 83(5):743-57. DOI: 10.1097/01.lab.0000069519.06988.24. View

14.

Johnston S, Kamolpatana K, Johnston G . Prostatic disorders in the dog. Anim Reprod Sci. 2000; 60-61:405-15. DOI: 10.1016/s0378-4320(00)00101-9. View

15.

Nascimento-Goncalves E, Faustino-Rocha A, Seixas F, Ginja M, Colaco B, Ferreira R . Modelling human prostate cancer: Rat models. Life Sci. 2018; 203:210-224. DOI: 10.1016/j.lfs.2018.04.014. View

16.

DeGrado T, Coleman R, Wang S, Baldwin S, Orr M, Robertson C . Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001; 61(1):110-7. View

17.

Kwee S, Wei H, Sesterhenn I, Yun D, Coel M . Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006; 47(2):262-9. View

18.

Goldspiel B, Kohler D . Flutamide: an antiandrogen for advanced prostate cancer. DICP. 1990; 24(6):616-23. DOI: 10.1177/106002809002400612. View

19.

Bhavsar A, Verma S . Anatomic imaging of the prostate. Biomed Res Int. 2014; 2014:728539. PMC: 4160650. DOI: 10.1155/2014/728539. View

20.

Creasy D, Bube A, de Rijk E, Kandori H, Kuwahara M, Masson R . Proliferative and nonproliferative lesions of the rat and mouse male reproductive system. Toxicol Pathol. 2012; 40(6 Suppl):40S-121S. DOI: 10.1177/0192623312454337. View